Jump to content

Dezandrodeg

Add links
From Wikipedia, the free encyclopedia

Dezandrodeg
Clinical data
Other namesAR-LDD; BMS-986365; BMS986365; CC-0094676; CC0094676; CC-94676; CC94676; CEL-007452; CEL007452
Routes of
administration		Oral[1]
Drug classAntiandrogen; Androgen receptor antagonist; Androgen receptor degrader
Identifiers
  • 2-[(2R)-4-[2-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-ethylphenoxy]ethyl]-2-methylpiperazin-1-yl]-N-[3-[(2,6-dioxopiperidin-3-yl)amino]phenyl]acetamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC41H45F3N8O5S
Molar mass818.92 g·mol−1
3D model (JSmol)
  • CCC1=C(C=CC(=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)OCCN4CCN([C@@H](C4)C)CC(=O)NC5=CC=CC(=C5)NC6CCC(=O)NC6=O
  • InChI=1S/C41H45F3N8O5S/c1-5-26-19-31(52-39(58)51(38(56)40(52,3)4)30-10-9-27(22-45)32(21-30)41(42,43)44)11-13-34(26)57-18-17-49-15-16-50(25(2)23-49)24-36(54)47-29-8-6-7-28(20-29)46-33-12-14-35(53)48-37(33)55/h6-11,13,19-21,25,33,46H,5,12,14-18,23-24H2,1-4H3,(H,47,54)(H,48,53,55)/t25-,33?/m1/s1
  • Key:YUVGVJYLOFTILT-NHYGQJMQSA-N

Dezandrodeg (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names BMS-986365 and CC-94676) is an antiandrogen which is under development for the treatment of prostate cancer.[1][2][3][4] It is taken orally.[1] The drug acts as a dual androgen receptor antagonist and androgen receptor degrader.[1][2][3][4] It is under development by Celgene Corporation and Bristol-Myers Squibb.[1][2] As of June 2026, dezandrodeg is in phase 3 clinical trials for prostate cancer.[1][2] It was also under development for the treatment of solid tumors, but no recent development has been reported.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 "Celgene Corporation". AdisInsight. 15 June 2026. Retrieved 28 July 2026.
  2. 1 2 3 4 "Delving into the Latest Updates on Dezandrodeg with Synapse". Synapse. 3 July 2026. Retrieved 28 July 2026.
  3. 1 2 Nayak S, Norris JD, Ammirante M, Rychak E, Wardell SE, Liao D, et al. (January 2026). "Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer". Clinical Cancer Research. 32 (1): 224–241. doi:10.1158/1078-0432.CCR-25-0471. PMC 12770934. PMID 40788283.
  4. 1 2 Mortensen DS, Nayak S, Plantevin-Krenitsky V, Horn EJ, Meiring J, Reiss S, et al. (July 2026). "Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365". Journal of Medicinal Chemistry. 69 (14): 16346–16362. doi:10.1021/acs.jmedchem.6c01590. PMID 42430428.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Dezandrodeg&oldid=1370222486"